Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?

The market didn't appreciate Amgen 's (NASDAQ: AMGN) latest clinical data update, with the biopharma's shares falling more than 12% at one point on Nov. 26 ... Read more

Bron:

Fool.com: The Motley Fool